OTCMKTS:AGNPF Algernon Pharmaceuticals (AGNPF) Stock Price, News & Analysis $0.06 0.00 (0.00%) As of 04/17/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About Algernon Pharmaceuticals Stock (OTCMKTS:AGNPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AGNPF alerts:Sign Up Key Stats Today's Range$0.06▼$0.0650-Day Range$0.05▼$0.0952-Week Range$0.04▼$0.12VolumeN/AAverage Volume18,536 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAlgernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.Read More… Receive AGNPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGNPF Stock News HeadlinesAlgernon Pharmaceuticals receives notice of allowance from EPO for RepirinastApril 9, 2025 | markets.businessinsider.comAlgernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney DiseaseApril 8, 2025 | financialpost.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 18, 2025 | Porter & Company (Ad)Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney DiseaseApril 8, 2025 | globenewswire.comAlgernon engages Netcapital Securities for Regulation A financingMarch 6, 2025 | markets.businessinsider.comAlgernon NeuroScience Engages Netcapital Securities for Planned Regulation A FinancingMarch 6, 2025 | financialpost.comAlgernon NeuroScience Engages Netcapital Securities for Planned Regulation A FinancingMarch 6, 2025 | globenewswire.comAlgernon Pharmaceuticals appoints Sandor Nardai as OI for Phase 2a DMT studyFebruary 11, 2025 | markets.businessinsider.comSee More Headlines AGNPF Stock Analysis - Frequently Asked Questions How have AGNPF shares performed this year? Algernon Pharmaceuticals' stock was trading at $0.0463 at the beginning of the year. Since then, AGNPF stock has increased by 29.6% and is now trading at $0.06. View the best growth stocks for 2025 here. When did Algernon Pharmaceuticals' stock split? Algernon Pharmaceuticals's stock split before market open on Friday, March 3rd 2023. The 4-1 split was announced on Friday, March 3rd 2023. The newly created shares were issued to shareholders after the market closes on Friday, March 3rd 2023. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. How do I buy shares of Algernon Pharmaceuticals? Shares of AGNPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:AGNPF CIK1642178 Webalgernonpharmaceuticals.com Phone604-398-4175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:AGNPF) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Algernon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.